Improvement of symptoms of Covid-19 patients

The World Health Organization Case Report Form (WHO-CRF) is for measuring the symptoms of Covid-19 of hospitalized patients. The forms are modified for Covid-19 outpatients. Therefore, 14 symptoms of the patients in the “treatment” and “control” groups were daily recorded over an 8-day period. For each symptom, the “effectiveness” and “significancy” of SaliraVira® versus “routine hospital drugs” are evaluated and compared. Specifically, “effectiveness” is indicated by the “probability of the symptom improvement” and “significancy” is stated by the “p-value of the symptom improvement”. The treatment improvements could be remarkably distinguished in days 4th, 6th, 7th, and 8th days declared as nth days in Table 1.

As shown in Table 1, in the 4th day of treatment, with a probability of at least 95% (or p-value < 0.05) the improvement of 3 out of 14 symptoms of Covid-19 (i.e., joint-pain, muscle-aches, wheeze) in “case” group were significantly and efficaciously preferred to “control” group. In the 6th day of treatment, with a probability of at least 90% (or p-value < 0.1) the improvement of 7 out of 14 symptoms of Covid-19 (i.e., sore-throat, headache, shortness-of-breath, decreased-smell, abdominal-pain, inability-to-walk, and rhinorrhea) in “case” group were significantly preferred to “control” group. Also, 4 out the 7 symptoms (i.e., headache, abdominal-pain, inability-to-walk, rhinorrhea) in “case” group efficaciously preferred to “control” group. In the 6th day of treatment, with a probability of at least 95% (or p-value < 0.05) the improvement of 5 out of 14 symptoms of Covid-19 (i.e., sore-throat, headache, shortness-of-breath, abdominal-pain, inability-to-walk) in “case” group were significantly preferred to “control” group.

Also, 4 out the 5 symptoms (i.e., sore-throat, headache, abdominal-pain, inability-to-walk) in “case” group efficaciously preferred to “control” group. In the 7 and 8thday treatment, with a probability of at least 90% (or p-value< 0.1) the improvement of 4 out of 14 symptoms of Covid-19 (i.e., decreased-taste, fatigue, altered-consciousness-confusion, chest-pain) in “case” group were significantly preferred to “control” group. Also, 2 out the 4 symptoms (i.e., fatigue, altered-consciousness-confusion) in “case” group efficaciously preferred to “control” group. In the 7and 8thdaytreatment, with a probability of at least 95% (or p-value< 0.05) the improvement of 2 out of 14 symptoms of Covid-19 (i.e., fatigue, altered-consciousness-confusion) in “case” group were significantly and efficaciously preferred to “control” group.

>> NEXT